Footnotes: Hazard ratios when comparing each regimen with Gemcitabine (G), projected median overall survival (OS), number needed to treat (NNT) at 6 months and 1 year when compared with G. Projected m
ObjectivesTo systematically review and meta-analyze the current literature in a methodologically rigorous and transparent manner for quantitative evidence on survival outcomes among patients diagnosed
Patients undergoing d-rad may have the same OS and HFS as those undergoing d-CRT. Patients attributed approximately 7% of their OS to hospitalization and outpatient consultation, regardless of the tre
